Protara Therapeutics' (TARA) "Sell (D-)" Rating Reiterated at Weiss Ratings

Key Points

• Protara Therapeutics' stock has been given a "sell (D-)" rating by Weiss Ratings, reaffirming concerns about the company's performance.
• The company's recent earnings per share (EPS) came in at ($0.35), exceeding analysts' expectations, but predictions for the current fiscal year remain negative at an average of (-3.32) EPS.
• Protara Therapeutics operates in the clinical-stage biopharmaceutical sector, focusing on transformative therapies for cancer and rare diseases, with its lead program currently in Phase II trials.

Protara Therapeutics (NASDAQ:TARA - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by equities research analysts at Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

Protara Therapeutics Trading Up 5.2%

Shares of TARA stock opened at $5.07 on Wednesday. Protara Therapeutics has a 12 month low of $1.60 and a 12 month high of $10.48. The stock has a market cap of $195.60 million, a PE ratio of -3.13 and a beta of 1.53. The company's fifty day moving average price is $3.45 and its 200-day moving average price is $3.45.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.08. On average, sell-side analysts forecast that Protara Therapeutics will post -3.32 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Protara Therapeutics

A number of large investors have recently made changes to their positions in TARA. Velan Capital Investment Management LP grew its stake in shares of Protara Therapeutics by 5.6% during the 1st quarter. Velan Capital Investment Management LP now owns 1,667,800 shares of the company's stock valued at $7,105,000 after acquiring an additional 88,800 shares during the period. Walleye Capital LLC lifted its stake in Protara Therapeutics by 3.9% in the 1st quarter. Walleye Capital LLC now owns 229,454 shares of the company's stock worth $977,000 after purchasing an additional 8,640 shares in the last quarter. American Century Companies Inc. purchased a new stake in Protara Therapeutics in the 1st quarter worth $154,000. Charles Schwab Investment Management Inc. purchased a new stake in Protara Therapeutics in the 1st quarter worth $64,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in Protara Therapeutics in the 1st quarter worth $320,000. 38.13% of the stock is currently owned by institutional investors.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.